Baird Medical starts registration process in US, EU & China
TL;DR
Baird Medical has completed development of its AI-driven surgical software and started regulatory registration in the US, EU, and China. The software integrates with robotic systems and aims to enhance surgical workflows, building on the company's existing market presence in microwave ablation technologies.
Tags
Baird Medical starts registration process in US, EU & China
Baird Medical Initiates Regulatory Registration for AI-Driven Surgical Software in Key Markets
On March 4, 2026, Baird Medical (NASDAQ: BDMD) announced the completion of development for its cross-platform, AI-driven surgical software and the initiation of regulatory registration processes in the United States, European Union, and China. The system, designed to automate anatomical mapping, dynamic treatment planning, and procedural simulations using a proprietary AI model, integrates diverse diagnostic imaging data and is engineered to interface with Baird's upcoming automated surgical robotic system. The company described the platform as a component of a closed-loop surgical ecosystem spanning pre-, intra-, and post-operative workflows, aiming to accelerate its commercial roadmap.
The regulatory filings follow Baird's established presence in the U.S. market, where its microwave ablation (MWA) technologies have been adopted by over 30 hospitals and clinics, including institutions such as Mayo Clinic and Weill Cornell Medical Center. The company has previously emphasized education and collaboration with U.S. endocrinologists and surgeons to expand access to minimally invasive therapies. In China, Baird is a market leader in thyroid MWA devices and has navigated evolving regulatory frameworks, including the 2021 Medical Device Administration Regulations (MDAR 2021), which introduced requirements for medical device holders and streamlined approval pathways for innovative products.
The AI-driven software's registration in multiple jurisdictions reflects Baird's strategy to scale its technological footprint. The system's integration with robotic surgical platforms underscores the company's focus on precision medicine and digital health innovation. However, regulatory approval timelines and market adoption remain subject to standard risks, including clinical validation and competitive dynamics.
Baird Medical's initiatives align with its broader goals to strengthen global partnerships and advance minimally invasive care. The company has previously expanded its U.S. operations through senior hires, partnerships, and educational programs, including participation in specialty conferences like NASOIE 2026.